menu
    • menu
    [{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Argenx","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody","year":"2022","type":"Agreement","leadProduct":"Efgartigimod Alpha","moa":"FcRn","graph1":"Immunology","graph2":"Approved FDF","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Argenx","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm Diosynth Biotechnologies \/ Argenx"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Termination","leadProduct":"Matrix-m1","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Novavax","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm Diosynth Biotechnologies \/ Novavax"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"US Government","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Matrix-M","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ US Government","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm Diosynth Biotechnologies \/ US Government"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Matrix-M","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm Diosynth Biotechnologies \/ BARDA"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Novavax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"Matrix-M","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Novavax","highestDevelopmentStatusID":"15","companyTruncated":"Fujifilm Diosynth Biotechnologies \/ Novavax"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-dependent DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"10","companyTruncated":"Fujifilm Diosynth Biotechnologies \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"Modified Horsepox Virus Vaccine, Live","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Percutaneous Injection","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"1","companyTruncated":"Fujifilm Diosynth Biotechnologies \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"Atara Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Tabelecleucel","moa":"EBV","graph1":"Immunology","graph2":"Phase III","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ Atara Biotherapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Fujifilm Diosynth Biotechnologies \/ Atara Biotherapeutics"},{"orgOrder":0,"company":"Fujifilm Diosynth Biotechnologies","sponsor":"aTyr Pharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"Efzofitimod","moa":"NRP2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II","graph3":"Fujifilm Diosynth Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fujifilm Diosynth Biotechnologies \/ aTyr Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Fujifilm Diosynth Biotechnologies \/ aTyr Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Fujifilm Diosynth Biotechnologies

    Menu

    Fujifilm Diosynth Biotechnologies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Fujifilm Diosynth Biotechnologies

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed

                            Fujifilm Diosynth Biotechnologies

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efgartigimod Alpha

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Argenx

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            FUJIFILM Diosynth Biotechnologies Enters into an Agreement with Argenx to Manufacture Efgartigimod, a Monoclon...

                            Details : Under the agreement, FUJIFILM Diosynth Biotechnologies will provide drug substance manufacturing of efgartigimod (Vyvgart) at its large-scale biomanufacturing facility in Hillerod, Denmark.

                            Product Name : Vyvgart

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            October 27, 2022

                            Lead Product(s) : Efgartigimod Alpha

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Argenx

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Fujifilm Diosynth Biotechnologies

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed

                            Fujifilm Diosynth Biotechnologies

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NVX-COV2373,Matrix-m1

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : Novavax

                            Deal Size : $185.0 million

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Amid Low Vaccine Demand, Novavax Pulls Out Of Fujifilm Manufacturing Deal And Inks $185M Settlement

                            Details : Novavax has been suffering from lower-than-expected demand for its COVID-19 vaccine (Nuvaxovid). Because of which Novavax will pay Fujifilm Diosynth Biotechnologies in a settlement tied to the "termination of manufacturing activity" at its CDMO partner.

                            Product Name : NVX-COV2373

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            September 30, 2022

                            Lead Product(s) : NVX-COV2373,Matrix-m1

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Novavax

                            Deal Size : $185.0 million

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Fujifilm Diosynth Biotechnologies

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed

                            Fujifilm Diosynth Biotechnologies

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tabelecleucel

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Atara Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Atara Biotherapeutics Announces the Completion of the Acquisition of Its Cell Therapy Manufacturing Facility &...

                            Details : FUJIFILM will provide Atara with access to the flexible capacity and specific capability needed to manufacture clinical and commercial-stage allogeneic cell therapies for its promising pipeline, including tabelecleucel (tab-cel®), ATA188, and allogeneic...

                            Product Name : Tab-cel

                            Product Type : Cell and Gene therapy

                            Upfront Cash : $100.0 million

                            April 04, 2022

                            Lead Product(s) : Tabelecleucel

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Atara Biotherapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Fujifilm Diosynth Biotechnologies

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed

                            Fujifilm Diosynth Biotechnologies

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efzofitimod

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : aTyr Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            aTyr Pharma and FUJIFILM Diosynth Biotechnologies Announce Manufacturing Agreement for aTyr’s Lead Therapeut...

                            Details : Under the terms of the agreement, FUJIFILM Diosynth Biotechnologies will support process development and scale up of ATYR1923, including the manufacture of bulk drug substance for additional clinical trials in ILD.

                            Product Name : ATYR1923

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            November 30, 2021

                            Lead Product(s) : Efzofitimod

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : aTyr Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Fujifilm Diosynth Biotechnologies

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed

                            Fujifilm Diosynth Biotechnologies

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NVX-COV2373,Matrix-M

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Novavax

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Fujifilm Diosynth Biotechnologies Expands Its Partnership with Novavax to Manufacture Covid-19 Vaccine Candida...

                            Details : FUJIFILM's site in Billingham, UK will manufacture antigen component of NVX-CoV2373, Novavax' COVID-19 vaccine candidate. Billingham plans to begin production of the first batch at beginning of Q1, 2021.

                            Product Name : NVX-COV2373

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            August 17, 2020

                            Lead Product(s) : NVX-COV2373,Matrix-M

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Novavax

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Fujifilm Diosynth Biotechnologies

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed

                            Fujifilm Diosynth Biotechnologies

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NVX-COV2373,Matrix-M

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : US Government

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            FUJIFILM Diosynth Biotechnologies Texas Facility to Support COVID-19 Vaccine Candidate Manufacturing

                            Details : FUJIFILM Diosynth will support COVID-19 vaccine candidate manufacturing, as part of Operation Warp Speed, a U.S. government program that aims to begin delivering millions of doses of a safe, effective vaccine for COVID-19 to the U.S. population.

                            Product Name : NVX-COV2373

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            July 27, 2020

                            Lead Product(s) : NVX-COV2373,Matrix-M

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : US Government

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Fujifilm Diosynth Biotechnologies

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed

                            Fujifilm Diosynth Biotechnologies

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Favipiravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Dr. Reddy's Laboratories

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Fujifilm to Begin Clinical Trials Testing Avigan in COVID-19 Patients in Kuwait

                            Details : Avigan (favipiravir) is an antiviral medication largely used to treat influenza in Japan. It was approved in the country in 2014 and became a generic drug in 2019.

                            Product Name : Avigan

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 21, 2020

                            Lead Product(s) : Favipiravir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Dr. Reddy's Laboratories

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Fujifilm Diosynth Biotechnologies

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed

                            Fujifilm Diosynth Biotechnologies

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NVX-COV2373,Matrix-M

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : BARDA

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BARDA drafts Fujifilm Diosynth into its vaccine production effort, offering to also accelerate capacity expans...

                            Details : FUJIFILM Diosynth Biotechnologies' College Station, Texas, site will support COVID-19 vaccine manufacturing, and Speed up U.S. government program to begin delivering millions of doses of COVID-19 vaccine to U.S. population.

                            Product Name : NVX-COV2373

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 08, 2020

                            Lead Product(s) : NVX-COV2373,Matrix-M

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : BARDA

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Fujifilm Diosynth Biotechnologies

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed

                            Fujifilm Diosynth Biotechnologies

                            United Kingdom arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Modified Horsepox Virus Vaccine, Live

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Tonix Pharmaceuticals Holding Corp

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Tonix Pharmaceuticals Announces FUJIFILM Diosynth Biotechnologies to be Manufacturing Partner for COVID-19 Vac...

                            Details : Under the agreement, Fujifilm Diosynth Biotechnologies will develop a manufacturing process, manufacture, and stock a supply of TNX-1800 at FDB’s College Station, Texas site for Tonix’s clinical development.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            January 06, 2020

                            Lead Product(s) : Modified Horsepox Virus Vaccine, Live

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Tonix Pharmaceuticals Holding Corp

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth